Stramsen Biotech Valued at $19 Billion as It Prepares Capital Markets Push and FDA Milestones

New updates have been reported about Stramsen Biotech Inc.

Stramsen Biotech Inc. has been independently valued at approximately $19 billion by Stonebridge Advisory Inc., a California-based appraisal firm, reflecting the company’s venture-backed position, plant-based drug portfolio, and long-term financial projections in the biopharmaceutical sector. The analysis incorporated factors such as the company’s FDA progress, management and scientific depth, total addressable market, and peer comparisons, and Stramsen has also reserved the trading symbol SBRX in anticipation of future capital markets activity.

Operationally, Stramsen is awaiting final feedback from the U.S. Food and Drug Administration following a Pre-IND meeting, a step that will determine the timing of its full IND submission for SBX-1977, a wound-care drug candidate central to its near-term development pipeline. To support its growth, the company is actively courting investment banks and law firms of various sizes for capital markets partnerships while highlighting plans to create hundreds of jobs in Houston and other U.S. biotech hubs as it advances a portfolio of 33 plant-based drug candidates and targets 1–5% of a combined $1.7 trillion herbal and general therapeutics market over the next 5–20 years.